Manas AI Secures $26 Million Seed Extension to Advance AI-Driven Drug Discovery Platform
核心洞察
Manas AI (搜索) has successfully closed a $26 million Seed Extension funding round to accelerate its AI-based drug discovery platform development.
The company appointed Ujjwal Singh, former Google (搜索) and Meta (搜索) executive, as Co-Founder and Chief Technology Officer to lead technological advancement.
The funding will support development of foundational AI models for drug discovery, progression of existing therapeutic campaigns, and team expansion.
Manas AI (搜索) has successfully closed a $26 million Seed Extension funding round to accelerate its artificial intelligence-driven drug discovery platform. The company simultaneously announced the appointment of Ujjwal Singh as Co-Founder and Chief Technology Officer, bringing extensive AI and product development experience to the leadership team.
The funding represents a significant milestone for the company's mission to address inefficiencies in traditional drug development processes. By integrating biomedical expertise with advanced AI capabilities, Manas AI (搜索) aims to create medications that are developed more quickly, at lower cost, and with greater therapeutic precision.
Strategic Deployment of Capital
The newly secured capital will be strategically deployed across several key areas. Primary focus will be on accelerated development of Manas AI (搜索)'s foundational models for drug discovery, which form the core of their technological platform. The funding will also support progression of existing therapeutic campaigns, bringing promising new treatments closer to clinical reality.
Additionally, Manas AI (搜索) plans to expand its interdisciplinary team by attracting top talent from various fields. This expansion will be guided by Singh's expertise as he builds out the company's technological capabilities.
Leadership Enhancement
Ujjwal Singh brings an impressive track record of leadership and innovation to Manas AI (搜索). Most recently, he served as Chief Technology and Product Officer at Multiverse (搜索), where he drove product strategy and technological development. Previously, he held the position of Head of Workplace at Meta (搜索), demonstrating his ability to lead large-scale product initiatives.
Singh's distinguished career includes significant tenure at Google (搜索), where he was a driving force behind numerous product innovations. At Google, he served as a Partner in the internal incubator Area 120, designed to foster experimental new products. As Senior Director of Engineering, he founded and launched Google Hangouts and spearheaded engineering efforts that expanded YouTube into dedicated platforms including YouTube Kids, YouTube Music, and YouTube Gaming.
Investment Backing
This Seed Extension round builds upon a previous $24.6 million Seed Round announced in January, which was led by General Catalyst (搜索) and Reid Hoffman. The current extension round saw participation from a diverse group of investors, including The General Partnership (搜索), Wisdom Ventures (搜索), Blitzscaling Ventures (搜索), Westbound Equity Partners (搜索), Mosaic Ventures (搜索), and several individual investors.
"We are incredibly excited to welcome Ujjwal Singh as both a Co-Founder and Chief Technology Officer," said Dr. Siddhartha Mukherjee, CEO and Co-Founder of Manas AI (搜索). "Ujjwal's extensive AI and productization background perfectly complement the AI-native, scalable design of Manas' vision. Ujjwal will not only make an impact on our cutting-edge AI capabilities but also as an experienced and visionary leader in the Co-Founder role."
Singh expressed his enthusiasm for the role, stating: "Manas AI (搜索)'s mission to usher in a new era of medicine—one defined by accelerated discovery and highly targeted therapies—deeply resonates with me. Together with Reid Hoffman, Dr. Siddhartha Mukherjee, and the rest of the remarkable leadership team, I believe we can build a truly meaningful company that harnesses and deploys the most impactful aspects of the AI revolution we are witnessing."
The appointment reflects the company's commitment to leveraging AI technology to transform pharmaceutical innovation and address the significant challenges facing traditional drug development processes.